Pages that link to "Q33724456"
Jump to navigation
Jump to search
The following pages link to Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial (Q33724456):
Displaying 50 items.
- Trastuzumab containing regimens for early breast cancer (Q24200192) (← links)
- Cardiac toxicity of trastuzumab in elderly patients with breast cancer (Q26741182) (← links)
- Adjuvant systemic therapy in older women with breast cancer (Q26741523) (← links)
- Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity (Q26744675) (← links)
- Infracentimetric HER-2 positive breast tumours-review of the literature (Q26774597) (← links)
- How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer (Q26824542) (← links)
- Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? (Q27025860) (← links)
- Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management (Q28068290) (← links)
- Treatment of early-stage HER2+ breast cancer-an evolving field (Q28081124) (← links)
- Cardiac risk in the treatment of breast cancer: assessment and management (Q28081385) (← links)
- Long term side effects of adjuvant chemotherapy in patients with early breast cancer (Q28083233) (← links)
- Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline (Q28260063) (← links)
- Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage (Q30439608) (← links)
- The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry (Q30659496) (← links)
- Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. (Q30663382) (← links)
- Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data (Q31004660) (← links)
- Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. (Q33427353) (← links)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update (Q33862786) (← links)
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab (Q33930241) (← links)
- Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors (Q33949465) (← links)
- Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (Q33964848) (← links)
- Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice (Q33976440) (← links)
- Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines (Q34023749) (← links)
- Optimizing the management of HER2-positive early breast cancer: the clinical reality (Q34035460) (← links)
- HER2 status and breast cancer therapy: recent advances (Q34062418) (← links)
- Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program (Q34155601) (← links)
- Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity (Q34189102) (← links)
- Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics (Q34255916) (← links)
- Targeting HER2 in breast cancer: overview of long-term experience (Q34272044) (← links)
- HER2 signaling pathway and trastuzumab cardiotoxicity (Q34328064) (← links)
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (Q34484185) (← links)
- Cardiovascular toxicities from systemic breast cancer therapy (Q34630349) (← links)
- Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study (Q34779675) (← links)
- Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients (Q34975825) (← links)
- Cardiac dysfunction after cancer treatment (Q35039549) (← links)
- Adjuvant Therapy for Women Over Age 65 With Breast Cancer (Q35051256) (← links)
- Pharmacoeconomic considerations in the treatment of breast cancer (Q35205385) (← links)
- Optimal systemic therapy for early breast cancer in women: a clinical practice guideline (Q35239634) (← links)
- Geriatric assessment in older patients with breast cancer (Q35428376) (← links)
- Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations (Q35490056) (← links)
- Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider (Q35583779) (← links)
- Early Breast Cancer in the Older Woman (Q35584539) (← links)
- Cardiovascular complications of breast cancer therapy in older adults (Q35584686) (← links)
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer (Q35609706) (← links)
- Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer (Q35687465) (← links)
- A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (Q35693076) (← links)
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer (Q35742760) (← links)
- Managing high-risk breast cancer (Q35819307) (← links)
- Lifestyle interventions for cardiovascular risk reduction in women with breast cancer (Q35878469) (← links)
- Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer (Q35880224) (← links)